Combination of PKCδ Inhibition with Conventional TKI Treatment to Target CML Models

SIMPLE SUMMARY: The tyrosine kinase inhibitor (TKI) imatinib was the first targeted therapy to show clinical efficacy against chronic myeloid leukemia (CML) through inhibition of the breakpoint cluster region–Abelson murine leukemia viral oncogene homolog (BCR-ABL), which is responsible for the dise...

Descripción completa

Detalles Bibliográficos
Autores principales: Muselli, Fabien, Mourgues, Lucas, Morcos, Rita, Rochet, Nathalie, Nebout, Marielle, Guerci-Bresler, Agnès, Faller, Douglas V, William, Robert M, Mhaidly, Rana, Verhoeyen, Els, Legros, Laurence, Peyron, Jean-François, Mary, Didier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038300/
https://www.ncbi.nlm.nih.gov/pubmed/33918475
http://dx.doi.org/10.3390/cancers13071693

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038300/
https://www.ncbi.nlm.nih.gov/pubmed/33918475
http://dx.doi.org/10.3390/cancers13071693

Ejemplares similares